- Home
- CANF vs ECPG Comparison
CANF vs ECPG Comparison
Compare CANF & ECPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ECPG
- Stock Information
- Founded
- CANF 1994
- ECPG 1998
- Country
- CANF Israel
- ECPG United States
- Employees
- CANF N/A
- ECPG N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ECPG Finance Companies
- Sector
- CANF Health Care
- ECPG Finance
- Exchange
- CANF Nasdaq
- ECPG Nasdaq
- Market Cap
- CANF 7.9M
- ECPG 806.1M
- IPO Year
- CANF N/A
- ECPG 1999
- Fundamental
- Price
- CANF $1.11
- ECPG $40.97
- Analyst Decision
- CANF Strong Buy
- ECPG Strong Buy
- Analyst Count
- CANF 2
- ECPG 3
- Target Price
- CANF $14.00
- ECPG $62.67
- AVG Volume (30 Days)
- CANF 444.9K
- ECPG 334.9K
- Earning Date
- CANF 05-20-2025
- ECPG 05-07-2025
- Dividend Yield
- CANF N/A
- ECPG N/A
- EPS Growth
- CANF N/A
- ECPG N/A
- EPS
- CANF N/A
- ECPG N/A
- Revenue
- CANF $674,000.00
- ECPG $1,380,750,000.00
- Revenue This Year
- CANF $461.72
- ECPG $21.62
- Revenue Next Year
- CANF N/A
- ECPG $10.12
- P/E Ratio
- CANF N/A
- ECPG N/A
- Revenue Growth
- CANF N/A
- ECPG 11.49
- 52 Week Low
- CANF $1.02
- ECPG $26.45
- 52 Week High
- CANF $4.69
- ECPG $51.77
- Technical
- Relative Strength Index (RSI)
- CANF 40.36
- ECPG 65.39
- Support Level
- CANF $1.02
- ECPG $32.27
- Resistance Level
- CANF $1.20
- ECPG $36.32
- Average True Range (ATR)
- CANF 0.06
- ECPG 1.54
- MACD
- CANF 0.01
- ECPG 0.87
- Stochastic Oscillator
- CANF 43.18
- ECPG 88.93
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.